|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
|
WO2004004693A1
(en)
|
2002-07-05 |
2004-01-15 |
Collgegium Pharmaceutical |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
|
JP2009530385A
(ja)
|
2006-03-22 |
2009-08-27 |
マウント シナイ スクール オブ メディシン |
うつ病の治療のためのケタミンの鼻内投与
|
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
CN105534936B
(zh)
|
2007-08-13 |
2020-07-31 |
Ohemo 生命科学股份有限公司 |
抗滥用药物、使用方法和制备方法
|
|
WO2009137843A2
(en)
|
2008-05-09 |
2009-11-12 |
Emory University |
Nmda receptor antagonists for the treatment of neuropsychiatric disorders
|
|
US20120225949A1
(en)
*
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
US20110038807A1
(en)
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
WO2013138322A1
(en)
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
JP2015521988A
(ja)
|
2012-07-06 |
2015-08-03 |
イガレット・リミテッド |
制御放出用乱用防止性医薬組成物
|
|
US20140079740A1
(en)
|
2012-08-02 |
2014-03-20 |
ClinPharm Support GmbH |
Oral transmucosal adminstration forms of s-ketamine
|
|
US9468611B2
(en)
|
2012-09-27 |
2016-10-18 |
Relmada Therapeutics, Inc. |
d-Methadone for the treatment of psychiatric symptoms
|
|
US10555916B2
(en)
|
2013-01-25 |
2020-02-11 |
Case Western Reserve University |
NMDAR antagonist for the treatment of pervasive development disorders
|
|
KR20220044380A
(ko)
|
2013-04-12 |
2022-04-07 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
외상후 스트레스 장애의 치료 방법
|
|
US9913803B2
(en)
|
2013-08-26 |
2018-03-13 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
|
WO2015066172A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EP3272338B1
(en)
|
2014-04-17 |
2020-09-09 |
Develco Pharma Schweiz AG |
Oral dosage form of ketamine
|
|
EP3193853A1
(en)
|
2014-09-15 |
2017-07-26 |
Janssen Pharmaceutica NV |
VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
|
|
KR102604397B1
(ko)
*
|
2014-11-04 |
2023-11-21 |
아카디아 파마슈티칼스 인코포레이티드 |
신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
WO2017041112A1
(en)
|
2015-09-04 |
2017-03-09 |
Cyprus Therapeutics, Inc. |
Ketamine and cytochrome p 450 inhibitor combinations
|
|
EP3377050A4
(en)
|
2015-11-17 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
|
|
WO2018079693A1
(ja)
|
2016-10-27 |
2018-05-03 |
国立大学法人 千葉大学 |
(s)-ノルケタミンおよびその塩の医薬品としての応用
|
|
WO2018102488A1
(en)
|
2016-11-30 |
2018-06-07 |
Wolfson Philip E |
Ketamine for the treatment of menstrually related symptoms
|
|
EP3641742B1
(en)
|
2017-06-23 |
2026-03-25 |
Ketabon GmbH |
Hydroxynorketamine for the use in the treatment of depression
|
|
MX2020003546A
(es)
*
|
2017-10-10 |
2020-08-03 |
Douglas Pharmaceuticals Ltd |
Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
|
|
SG11202005896WA
(en)
|
2017-12-22 |
2020-07-29 |
Janssen Pharmaceuticals Inc |
Esketamine for the treatment of depression
|
|
CA3103440A1
(en)
|
2018-06-27 |
2020-01-02 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
WO2020070706A1
(en)
|
2018-10-05 |
2020-04-09 |
Clexio Biosciences Ltd. |
Dosage regime of esketamine for treating major depressive disorder
|
|
US11324707B2
(en)
|
2019-05-07 |
2022-05-10 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
EP3923920A4
(en)
|
2019-08-05 |
2022-11-23 |
The Ketamine Research Foundation |
KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
WO2021137147A1
(en)
|
2019-12-30 |
2021-07-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|